MARKET

PRTA

PRTA

Prothena
NASDAQ
14.17
+0.28
+2.02%
Closed 19:45 02/14 EST
OPEN
13.99
PREV CLOSE
13.89
HIGH
14.53
LOW
13.63
VOLUME
204.63K
TURNOVER
0
52 WEEK HIGH
31.03
52 WEEK LOW
11.70
MARKET CAP
762.47M
P/E (TTM)
-5.7050
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PRTA last week (0210-0214)?
Weekly Report · 23h ago
Weekly Report: what happened at PRTA last week (0203-0207)?
Weekly Report · 02/10 09:15
Prothena Is Maintained at Outperform by Oppenheimer
Dow Jones · 02/07 18:02
Deep Dive Into Prothena Corp Stock: Analyst Perspectives (5 Ratings)
Benzinga · 02/07 18:00
Prothena price target raised to $62 from $58 at Oppenheimer
TipRanks · 02/07 13:20
Weekly Report: what happened at PRTA last week (0127-0131)?
Weekly Report · 02/03 09:16
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
NASDAQ · 01/30 17:11
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 01/28 22:10
More
About PRTA
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

Webull offers Prothena Corporation PLC stock information, including NASDAQ: PRTA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRTA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRTA stock methods without spending real money on the virtual paper trading platform.